Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
Academic rigour, journalistic flair
Articles on Alzheimer's disease
Displaying 101 - 120 of 351 articles
A clearer understanding of the true treatment costs of dementia for American Indian and Alaska Native adults could help health services better meet the needs of the populations they serve.
While longer naps are a normal part of aging, excessively long dozes could be a warning signal for cognitive decline.
If replicated in humans, these findings could mean that targeting or boosting the circadian rhythm in Alzheimer’s patients, could help with managing the disease
Research shows that violence between patients is prevalent, often overlooked and largely unaddressed.
In tough conversations, show your respect for loved ones’ autonomy and dignity.
The symptoms of menopause, which can include sleep disturbance, depression, anxiety and ‘brain fog’ can span perimenopause and last for up to ten years.
People who were more active had lower levels of inflammation in their brain.
The researchers found that people who slept less than 4.5 hours and more than 6.5 hours every night had a greater risk of cognitive decline.
Our research suggests the multiplication of protein aggregates in individual regions of the brain, rather than their spread between regions, is key to the progression of Alzheimer’s disease.
PET scans using a special tracer can pick up ‘tau tangles’ in the brain.
Arts-related activities for people living with Alzheimer’s and other related disorders could improve people’s quality of life, but collaborating in communities requires a common language.
New diagnostic tool for dementia could improve early detection.
Hyperbaric oxygen therapy helped to reduce plaques in the brains of mice with Alzheimer’s disease.
To stay healthy, it’s important to understand how wildfire smoke can harm your body and how to protect yourself.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Alzheimer’s disease is often associated with a decline in episodic memory. Patients will complain that they can’t remember events they’ve experienced, conversations they’ve had, things they’ve done.
Using a technique called admixture mapping, researchers can leverage the diversity of people with mixed ancestry to look for hard-to-find genetic risk factors for diseases like Alzheimer’s disease.
Insight on how a unique protein plays a role in cellular stress responses may provide more clues on how to treat diseases like ALS and Alzheimer’s.
Clinical trials of the drug have shown mixed results.
Top contributors
-
Research Fellow in Neuroimmunology, UCL
-
Associate Professor, Turner Institute for Brain and Mental Health, Monash University
-
Professor of Neurology and Neuroscience, University of Florida
-
Professor Emeritus of Molecular Neurobiology at the University of Manchester and a Visiting Professorial Fellow, University of Oxford
-
Professor of Neurology, UCL
-
Professor of Psychology in Epidemiology, UCL
-
Post grad student at University of Edinburgh, The University of Edinburgh
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Professor of Chemistry and Senior Scientist of the Krembil Research Institute, University Health Network, University of Toronto
-
Associate Professor in Cellular Neuroscience, University of Reading
-
Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
-
Investigations Editor, Insights, The Conversation
-
Associate Professor of Medicine and Geriatrics, University of Virginia
-
Editor and Co-Host, The Conversation Weekly Podcast, The Conversation
-
Postdoctoral Research Fellow, Tufts University
